Real-world Experience With Lutetium (177Lu) Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer, an Observational, Multicenter, Prospective Cohort Study
Latest Information Update: 16 Jan 2025
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 04 Oct 2024 Status changed from not yet recruiting to recruiting.
- 29 Jul 2024 New trial record